Actuate Therapeutics announces new data from Phase 2 trial of elraglusib

Actuate Therapeutics (ACTU) announced new positive data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first line treatment of metastatic pancreatic ductal adenocarcinoma, mPDAC. A pre-specified analysis was triggered by reaching greater than70% death events in the GnP control arm. The analysis of interim data demonstrated treatment with elraglusib in combination with GnP resulted in statistically significant increases in 1-year survival rate (p value of 0.002) and median overall survival versus treatment with GnP alone. The combination treatment also resulted in increased Objective Response Rates and Disease Control Rates in the elraglusib/GnP combination arm versus the GnP control arm.